Johnson & Johnson vs Pfizer at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | JNJ | PFE |
|---|---|---|
| Market cap | $666.49B | $162.82B |
| Price | $273.14 | $28.57 |
| P/E ratio (TTM) | 18.74 | 17.56 |
| P/B ratio (MRQ) | 6.16 | 1.58 |
| P/S ratio (TTM) | 5.33 | 2.18 |
| Revenue growth (1Y) | 6.05% | -1.65% |
| Return on equity (TTM) | 32.87% | 8.99% |
| Return on invested capital (TTM) | 16.26% | 10.60% |
| Gross margin (TTM) | 75.17% | 71.32% |
| Net margin (TTM) | 21.48% | 6.81% |
| Dividend yield (TTM) | 1.96% | 6.02% |
How they differ
Johnson & Johnson is the larger company at $666.49B versus $162.82B — about 4.1x the size.
On trailing earnings, Pfizer is the cheaper of the two at 17.56 against 18.74 for Johnson & Johnson.
On sales, Pfizer is the cheaper of the two at 2.18 against 5.33 for Johnson & Johnson.
Johnson & Johnson leads on revenue growth over the past year, 6.05% against -1.65%.
Johnson & Johnson leads on return on invested capital, 16.26% against 10.60%.
Johnson & Johnson leads on gross margin, 75.17% against 71.32%.
Pfizer offers the higher yield at 6.02% against 1.96%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Johnson & Johnson or Pfizer.